Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus ...

IQIRVO ® (elafibranor) is the first new ... of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

1 Elafibranor, a 'first-in-class' molecule marketed and ... trademark Iqirvo® since June 2024 for the treatment of Primary Biliary Cholangitis (PBC), was developed by GENFIT, from initial ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis.

ABILENE, Texas — April is national 9-1-1 education month. It's a reminder that knowing when to call 9-1-1 can make all the difference. From medical emergencies to crimes in progress, local ...

"After so many disappointments in this space, the first positive results from ... as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international ...